| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.1 | 0.08 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.057 | 0.08 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.09 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.09 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | -0.094 | 0.09 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.09 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | -0.075 | 0.09 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.09 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.09 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | -0.18 | 0.09 |